|
|
Time |
Source |
|
Announcement
|
|
| 11 Sep 2019 |
9:30 pm |
GNW
|
|
|
ObsEva SA |
ObsEva announces new composition of its Executive Committee |
| 03 Sep 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF |
| 30 Aug 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Upcoming Investor Conferences |
| 09 Aug 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13-14, 2019 |
| 07 Aug 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports Second Quarter 2019 Financial Results |
| |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC |
| 05 Aug 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019 |
| 26 Jul 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022 |
| 18 Jul 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares |
| 17 Jul 2019 |
5:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban |
| 12 Jul 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City |
| 08 Jul 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids |
| 01 Jul 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs |
| 21 Jun 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna |
| 19 Jun 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting |
| 04 Jun 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes |
| 16 May 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Upcoming Investor Conferences |
| 09 May 2019 |
6:15 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports First Quarter 2019 Financial Results |
| |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe |
| 08 May 2019 |
9:30 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019 |
| 03 May 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain |
| 01 May 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019 |
| 29 Apr 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF |
| 01 Apr 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Upcoming Investor Conferences |
| 29 Mar 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders |
| 13 Mar 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019 |
| 05 Mar 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update |
| 27 Feb 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019 |
| 22 Feb 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Upcoming Investor Conferences |
| 23 Jan 2019 |
8:28 am |
GNW
|
|
|
ObsEva SA |
Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial |
| 02 Jan 2019 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019 |
| 21 Dec 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids |
| 07 Dec 2018 |
5:12 pm |
GNW
|
|
|
ObsEva SA |
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations |
| 06 Dec 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018 |
| 29 Nov 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Host R&D Investor Day December 7, 2018 |
| 28 Nov 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes |
| 08 Nov 2018 |
6:15 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update |
| 07 Nov 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in November Investor Conferences |
| 31 Oct 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018 |
| 09 Oct 2018 |
9:15 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting |
| 05 Oct 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018 |
| 03 Oct 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET) |
| 28 Sep 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain |
| 28 Aug 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in September Investor Conferences |
| 10 Aug 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018 |
| 08 Aug 2018 |
6:00 am |
GNW
|
|
|
ObsEva SA |
ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update |
| 31 Jul 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018 |
| 25 Jul 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva Expands Executive Team Hiring a Chief Commercial Officer |
| 13 Jul 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA to start trading today on the SIX Swiss Exchange |
| 06 Jul 2018 |
6:30 am |
GNW
|
|
|
ObsEva SA |
ObsEva SA Shares to Begin Trading on SIX Swiss Exchange |
| 20 Jun 2018 |
7:49 am |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Pricing of Follow-on Public Offering |
| 18 Jun 2018 |
9:31 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Launch of Proposed Follow-on Public Offering |
| |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis |
| 15 Jun 2018 |
9:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018 |
| 01 Jun 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Seek SIX Share Listing |
| 31 May 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018 |
| 16 May 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update |
| 08 May 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018 |
| 23 Apr 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109) |
| 16 Apr 2018 |
12:00 pm |
GNW
|
|
|
ObsEva SA |
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City |